ISRCTN18186313
Completed
Not Applicable
A randomised trial of 6 months versus 12 months withdrawal of methotrexate in patients with Juvenile Idiopathic Arthritis (JIA) in clinical remissio
Pediatric Rheumatology International Trials Organisation (PRINTO) (Italy) and Wyeth Pharma0 sites300 target enrollmentFebruary 16, 2006
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Juvenila Idiopathic Arthritis (JIA)
- Sponsor
- Pediatric Rheumatology International Trials Organisation (PRINTO) (Italy) and Wyeth Pharma
- Enrollment
- 300
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients will be included at first confirmation of remission on medication i.e. after clinically documented inactive disease for at least three months (no joints with active arthritis, no fever, rash, serositis, splenomegaly, or generalized lymphadenopathy attributable to JIA, no active uveitis, no elevation in Erythrocyte Sedimentation Rate \[ESR] and/or C\-Reactive Protein \[CRP] attributable to JIA, physician?s global assessment of disease activity indicates no disease activity).
- •At three months, patients may be only be on a combination of Non\-Steroidal Anti\-Inflammatory Drugs (NSAIDs), low\-dose steroids (0\.2 mg/kg per day or 10 mg per day whichever is lower), and MTX (max 15 mg/m^2 per week); all the other drugs (e.g. biologics) must have been withdrawn before this date according to the physician?s decision.
- •Before inclusion into this study (study time point 0 months), patients will be considered to be in clinically documented remission on medication. At this time point, all medications other than NSAIDs and MTX with a dose range of 10 to 15 mg/m^2 per week have to be withdrawn. After discontinuation of MTX (study time point 6 i.e. after 6 months in group 1; study time point 12 i.e. after 12 months in group 2\) treatment with NSAIDs should be stopped.
Exclusion Criteria
- •Patients should not have received intra\-articular corticosteroids up to three months prior to inclusion
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A randomised trial of 6 months versus 12 months withdrawal of methotrexate in patiebts with juvenile idiopathic arthritis in clinical remission.Ensayo aleatorizado de retirada de Metotrexate a los 6 meses versus a los 12 meses, en pacientes con Artritis Idiopática Juvenil (AIJ) en remisión clínica - MTX withdrawal studyThe present study was designed for the follow up of two groups of patients with JIA, in whom remission was achieved using MTX. In group 1 treatment with MTX will be discontinued as early as 6 months after documentation of remission on medication. In group 2 treatment with MTX will be discontinued later than 12 mpnths after documentation of remission on medication.EUCTR2005-001086-34-ESIstituto Giannina Gaslini-PRINTO200
Active, not recruiting
Not Applicable
A randomised trial of 6 months versus 12 months withdrawal of methotrexate in patients with juvenile idiopathic arthritis in clincal remission - MTX withdrawal studyThe present study was designed for the follow up of two groups of patients with JIA, in whom remission was achieved using MTX. In group 1 treatment with MTX will be discontinued as early as 6 months after documentation of remission on medication. In group 2 treatment with MTX will be discontinued later than 12 months after documentation of remission on medicationEUCTR2005-001086-34-DKISTITUTO GIANNINA GASLINI-PRINTO200
Active, not recruiting
Not Applicable
A randomised Phase III trial of 6 months versus 12 months withdrawal of methotrexate in patients with juvenile idiopathic arthritis in clinical remissiojuvenile idiopathic arthritisMedDRA version: 6.1Level: PTClassification code 10059177EUCTR2005-001086-34-ITISTITUTO GIANNINA GASLINI
Recruiting
Not Applicable
TB Duration StudyCTRI/2020/03/023957Hyderabad Eye Resesarch Foundation
Completed
Phase 2
Randomized trial of clinical effect of 6 months or 3months Gn-RH agonist (Goserelin acetate 1.8mg) to endometriosis comlicated uterine myomaJPRN-UMIN000026073Department of Obstetrics and Gynecology Nara Medical University80